Overview

A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity

Status:
COMPLETED

Trial end date:
2025-05-09

Target enrollment:

Participant gender:

Summary

The primary objective of this trial is to evaluate the pharmacokinetics (PK) of AMG 133 administered alone and in combination with an antiemetic medication, ondansetron, in participants living with overweight or obesity.

Phase:

PHASE1

Details

Lead Sponsor:

Amgen

Treatments:

Ondansetron